Dianthus Therapeutics (DNTH) Misses Q3 EPS by 74c

Dianthus Therapeutics (NASDAQ: DNTH) reported Q3 EPS of ($0.74). Revenue for the quarter came in at $2.17 million.

For earnings history and earnings-related data on Dianthus Therapeutics (DNTH) click here.

You May Also Be Interested In

• Morgan Stanley Downgrades Qifu Technology (QFIN) to Equalweight
• Dycom Industries (DY) Tops Q2 EPS by 59c, Beats on Revenue
• BMO Capital Reiterates Market Perform Rating on Meta Platforms Inc. (META), 'will face engagement questions and continued capex ROI concerns'